newsfilter
← Latest News
GlobeNewswire·

NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022

Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company's lead myotonic dystrophy type 1 (DM1) candidate; new preclinical data to be presented at the American Society of Gene an